Epigral
Chemicals · EPIGRAL
Small CapBasic MaterialsHigh Growth
Maulik Patel
Chairman & Managing Director · Transformational
Company DNA
Performance-Driven
About
Epigral is a Small Cap company in the Basic Materials sector, listed on NSE as EPIGRAL. With a market cap of ₹4K Cr and revenue of ₹3K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Chemical sector manufacturer characterized by rapid capacity expansion and performance-oriented operational strategies under leadership. Its strategic mandate: As a specialty chemicals player, moving up the value chain through R&D-led product innovation is critical to differentiate from commodity peers.
FAQ
What kind of company is Epigral?
Epigral is a Small Cap Basic Materials company (EPIGRAL) in the High Growth phase with a market cap of ₹4K Cr. It is classified as Performance-Driven in culture.
What is Epigral's culture and work environment like?
Epigral has a Performance-Driven culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Chemical sector manufacturer characterized by rapid capacity expansion and performance-oriented operational strategies under leadership.
Who leads Epigral?
Epigral is led by Maulik Patel (Chairman & Managing Director), a Transformational leader with 20 years of experience.
What are Epigral's financials?
Epigral reported revenue of ₹3K Cr in FY25 with a 5-year revenue CAGR of 17.5%. Operating margin: 23%. Market cap: ₹4K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
Chemical sector manufacturer characterized by rapid capacity expansion and performance-oriented operational strategies under leadership.
Mandate
As a specialty chemicals player, moving up the value chain through R&D-led product innovation is critical to differentiate from commodity peers.
As a specialty chemicals player, moving up the value chain through R&D-led product innovation is critical to differentiate from commodity peers.
Financials
Revenue FY25₹3K Cr
PAT FY25₹358 Cr
Rev CAGR 5Y17.5%
OPM23%
NPM14.2%
ROE18.8%
ROCE21.7%
P/E11.1
Fwd P/E10.8
P/B1.8
D/E25.6
Mkt Cap₹4K Cr
Promoter68.9%
Institutional6.1%
Similar Culture
Could You Lead Epigral?
Take the Genome Benchmark →